This immunotherapy approach involves isolating TILs from the patient’s tumor, expanding them ex vivo with the assistance of recombinant IL-2 (rIL-2), and re-introducing amplified TILs into the patient to proliferate, recognize, and effectively eliminate the tumor cells (123). The gene discussed is IL2; the disease is neoplasm.